Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 341 clinical trials
featured
Atrial Fibrillation

of ischemic stroke or systemic embolism in subjects with non-valvular atrial fibrillation who have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation.

stroke
vascular disease
heart failure
ticagrelor
transient ischemic attack
  • 618 views
  • 03 Dec, 2020
  • 1 location
featured
Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)

Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)

atrial flutter
stroke
apixaban
vascular disease
cardiac monitoring
  • 314 views
  • 24 Nov, 2020
  • 1 location
featured
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

  • 30 views
  • 25 Mar, 2021
  • 1 location
featured
Aneurysm - HUD - Humanitarian Use Device - device to use with embolic coils for treatment of wide-neck, intracranial, saccular or fusiform aneurysms.

Aneurysm - HUD - Humanitarian Use Device - device to use with embolic coils for treatment of wide-neck, intracranial, saccular or fusiform aneurysms.

  • 80 views
  • 08 Nov, 2020
  • 1 location
featured
Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)

Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)

  • 76 views
  • 25 Mar, 2021
  • 1 location
STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Pulmonary embolisms (PE) occur when blood clots cause a blockage of the blood supply to the lungs. A small PE located in the subsegmental pulmonary vasculature is identified as a subsegmental PE (SSPE). Anticoagulants are used to treat SSPE and work by preventing new clots from forming whilst the body's …

  • 0 views
  • 25 Apr, 2021
  • 1 location
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

embolism and mortality. C. Other results include myocardial infarction, pulmonary embolism, transient ischemic attack, hospitalization, drug compliance, quality of life questionnaire (AFEQT), cognitive

  • 0 views
  • 25 Jan, 2021
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be

  • 0 views
  • 23 Jan, 2021
  • 16 locations
Clinical Study of Argatroban in the Treatment of Acute Progressive Ischemic Stroke

of the important pathogenesis of PIS. Heparin can reduce the incidence of post-stroke embolism, but its benefits are offset by the risk of hemorrhage due to the high risk of hemorrhage. The 2013AHA

  • 0 views
  • 25 Jan, 2021
  • 6 locations
TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)

TENecteplase in Central Retinal Artery Occlusion (TenCRAOS): A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomization). A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + …

  • 0 views
  • 15 Mar, 2021
  • 25 locations